Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma

Journal Article · · J. Clin. Endocrinol. Metab., v. 42, no. 1, pp. 105-111
The effect of lithium on iodine kinetics after oral $sup 131$I-iodide was studied in an athyreotic patient with follicular thyroid carcinoma. Lithium decreased the disappearance rate of $sup 131$I from the whole body and from a tumor mass in the patient's thigh from control values of 0.126/day and 0.122/day to 0.090/day and 0.049/day, respectively, while having only a minimal effect on the rate of $sup 131$I disappearance from blood. The increased tumor $sup 131$I retention would be expected to increase the therapeutic:toxic ratio of $sup 131$I. However, a subsequent therapeutic dose of $sup 131$I-iodide given with lithium was accompanied by an unanticipated increase in blood $sup 131$I and, therefore, in whole body radiation, resulting in significant bone marrow depression. Although lithium may be a useful adjunct in $sup 131$I therapy of functional thyroid carcinoma, it must be used cautiously in future studies. (auth)
Research Organization:
National Inst. of Health, Bethesda, MD
Sponsoring Organization:
USDOE
NSA Number:
NSA-33-026224
OSTI ID:
4036544
Journal Information:
J. Clin. Endocrinol. Metab., v. 42, no. 1, pp. 105-111, Journal Name: J. Clin. Endocrinol. Metab., v. 42, no. 1, pp. 105-111; ISSN JCEMA
Country of Publication:
United States
Language:
English